Varian Receives IDE: Prepares for 1st Ever Clinical Trial of FLASH Therapy

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

October 12, 2020

Varian has announced the company has received an Investigational Device Exemption (IDE) from the Food and Drug Administration (FDA) for the first-ever clinical trial of FLASH therapy, an experimental treatment modality delivering radiation therapy at ultra-high dose rates.

FLASH therapy, involving ultra-high dose rates, and delivery in typically less than one second, may be over 100 times faster compared to conventional radiation therapy. The study, named FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases), will involve the investigational use of Varian’s ProBeam® particle accelerator modified to offer this advanced non-invasive treatment option for patients with cancer.

The concept of ultra-high dose rate radiation delivery has been studied for many years. Dedicated research and development by Varian has led the advancement to the clinical study stage.  Varian’s efforts include investing in bench and preclinical research and supporting the FlashForward Consortium, a 20-member group of institutions from around the world, which includes experts in radiation oncology, translational sciences, and medical physics.

“FLASH therapy could be one of the most significant advancements in cancer treatment in decades,” said Kolleen Kennedy, Chief Growth Officer and President of Proton Therapy Solutions at Varian. “Our progress in advancing FLASH therapy on the ProBeam platform is a testament to Varian’s investments in research that improve care for patients with cancer and the importance of our collaboration with clinicians around the world through the FlashForward Consortium.”

The FAST-01 Feasibility Study, which is expected to enroll 10 patients with bone metastases, will evaluate clinical workflow feasibility, treatment-related side effects and efficacy of treatment as assessed by measuring trial participants’ pain relief.

“Preclinical research of FLASH therapy indicates using ultra-high dose rates may be less toxic overall and enhance sparing of adjacent healthy tissue,” added Deepak “Dee” Khuntia, M.D., Senior Vice President and Chief Medical Officer of Varian. “The study is an important proof of concept, especially in deep-seated and not just superficial tumors, that adds to a growing body of data necessary to advance our understanding of how FLASH therapy works.”

Varian anticipates enrollment of the first patient in the FAST-01 Feasibility Study by the end of 2020.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.